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INTRODUCTION
Pyoinflammatory pathological states have been the topical issue in the maxillofacial surgery. Thus, according to the latest data odontogenic phlegmons cause 30-40% of all maxillofacial diseases allowing to regard this pathology not only as a medical problem but also as an important social issue [1] [2] [3] . In 65% of all cases the clinical pattern phlegmons of the maxillofacial area is inconsistent with the topi cal diagnostics and the relevant local manifestations making it difficult to provide early and precise diagnostics as well as the required care delivery [4] . The quantity of patients with the vague clinical pattern and inert course of disease have been increasing making the diagnostics of inflammatory complications coursed by phlegmons (mediastinitis, intracerebral complications, sepsis, facial vein and cavernous sinus thrombosis) more challenging [5, 6] .
Cytokines (interleukins -IL) serving as the immune system mediators perform the universal regulatory function [7] [8] [9] . IL-7 was proved to regulate and activate the synthesis of IL-6 and IL-8 [10, 11] . The activation of macrophage and neutrophil chemokinesis in the inflammation focus area is the key immunobiological role of IL-17. IL-17 is generated by T-helpers [12] [13] [14] . IL-6 links cells in the inflammation focus and other tissues to achieve the most adequate response and agent's elimination. IL-6 is the main finishing stage inducer of the macrophage and B-lymphocyte differentiation [15, 16] . IL-8 is one of the early inflammation mediators referring to the chemokine group. It plays a significant role in causing and maintaining inflammation, in the migration of neutrophils into the inflammation focus and in the activation of the adhesion molecule synthesis. The activated mac rophages, monocytes and endothelial cells are main IL-8 producing cells [17, 18] .
In the up-to-date clinical practice the treatment result depends on the early and relevant diagnostics, therapeutic approaches with due account for the special aspects of the wound process course. The investigation of cytokine immune regulation mechanisms revealed in the course phlegmons of maxillofacial area is a topical medical issue.
The aim of the research is to investigate the dynamics of the amount of IL-17, IL-6, IL-8 in the blood serum of patients with phlegmons of the maxillofacial area.
METHODS
35 apparently healthy people (the observational group) were examined, 34 of which were suffering from phlegmons localized in one anatomical area (the 1 st group), phlegmons located in two anatomical groups (the 2 nd group) were revealed in 35 patients; the localization of phegmons in three or more anatomical areas was observed in 20 patients (the 3 rd group). Diagnosis was determined according to the patients complaints, disease and life history, objective and local status, clinical and laboratory tests. The patients underwent surgical intervention, the suppurative focuses were prosected, postsurgical wounds were drained and the "causative teeth" were removed.
The level of IL-6, IL-8 and IL-17 in the blood serum was defined by applying enzyme multiplied immunoassay using the set of chemical agents and following the instructions set by the "Diaclone" producer (France). Examination was conducted three times: before treatment (the 1 st day), on the 5 th and 9 th days following the surgery.
The correct allocation received in the primary results was reviewed by applying Shapiro Wilk test having shown the evidence of the Gaussian allocation type. The research results are shown as arithmetic average values and standard deviations (M±m). t Student criterion along with Bonferroni's adjustment were applied for estimating possible differences between the two groups. The correlation relations between the received indexes were studied by applying Pearson's code. Main calculations were made in Excel 2013.
RESULTS AND DISCUSSION
The level of IL-6, IL-8 and IL-17 revealed in the observational group and in patients is shown in Table 1 -3. The level of cytokines observed in the blood serum of patients under study was higher than that in the observational group.
The possible changes of IL-6 level as compared to the control carried out on the 1 st and 9 th day were not revealed in the 1 st group. The IL-6 level in the 2 nd group was exceeding the control rate and the 1 st group indexes (Р˂0.05) during 9 days but was apparently the same on the 1 st , 5 th and 9 th days. This index was 5 times higher on the 1 st day in the 3 rd group as compared to the 1 st group, 1.6 times higher than in the 2 nd group and 3.8 times higher than in the observational group (Р<0.05). The 1.5 decrease of cytokine level (Р<0.05) in comparison with the previous value was observed being apparently caused by the process chronization: the period with no clinical manifestations and the residual purulence revealed after suppurative focuses have been prosected and drained. The increase of IL-6 level in 2.4 times was observed on the 9 th day. IL-6 penetrates into the system circulation causing distant affects. The decrease of IL-6 followed by its sharp rise without any satisfactory dynamics is a predictably unfavourable factor that shall be taken into consideration while giving the integrated evaluation of indications for planning the treatment of a suppurative wound. The increase of IL-6 generation gives evidence of the protective mechanism required for the initial inflammation stage. Nevertheless, in cases when an inadequate increase of the activation degree is revealed the protective mechanism turns into a pathological one.
IL-6 activates the surrounding tissues and IL-8 is a chemokine for hemophage causing inflammation. The highest IL-8 level (13 times exceeding the control rate) was revealed in the 3 rd group on the 1 st day (Р<0.05) complying with the maximum activation of immune cells in the inflammation focus and allowed to predict a more severe course of disease. A tendency of IL-8 decreasing up to the 9 th day was observed in the course of treatment, though the index was 7 and 8.6 times apparently exceeding the control rate in the 2 nd and 3 rd groups correspondingly. The increase of cytokine level in the examined groups complied with the severity of phlegmons manifestations. Correspondingly, the increased IL-8 level in blood serum intensifies the local inflammation process.
One should note that the possible increase of IL-17 level in patients suffering from phlegmons of the maxillofacial area is the evidence of severe inflammation. A positive dynamics was observed in the 1 st group: the level of IL-17 decreased 1.8 times on the 9 th day in comparison with the 1 st day and was approaching the normal physiological rates. The apparent decrease of IL-17 level was revealed in the 2 nd group being 3 times higher than in the observational group on the 9 th day. The received result proves the evidence of a highly activated inflammation process. On the 5 th day cytokine under study decreased in the 3 rd group as compared to the initial value at that exceeding the relevant indexes of healthy people (Р˂0.05). The level of IL-17 on the 9 th day increased as compared to the 5 th day (Р˂0.05): apparently exceeding the control rate, the 1 st and the 2 nd groups in 8.5, 5.7 and 2.7 times correspondingly. Thus, the high level of IL-17 shows the disease severity, ineffective treatment and the risk of possible complications.
The levels of IL-6, IL-8 and IL-17 decrease in parallel with the regression of clinical symptoms though being still increased and, thus, indicating inflammation.
Comparing the outcomes of the groups under study one should note that the excessive production of cytokines on the 9 th day gives evidence to the inflammation generalization and to the turning of a local process into a systemic one requiring treatment correction.
Pair correlation coefficients between proinflammation cytokines in patients with phlegmons of the maxillofacial area were defined.
In case of no pathology and under normal conditions subtle correlation relations are observed in immune system allowing for a reasonable correction of slight homeostasis deviations inducing no stress in the system. In cases phlegmons of the maxillofacial area and with evident pathological findings the density and quantity Dynamics of proinflammatory cytokines at phlegmons of the maxillofacial area 2 nd group) 13.5±0.7*,** 9.5±0.4*,** 7.0±0.4*,** in three and more areas (the 3 rd group) 20.9±0.4*,** 17.0±0.4*,**,*** 18.9±0.9*,**,*** ing is caused by the activation of IL-6, IL-8, IL-17 generation.
The establishing of critical levels of cytokines involved in phlegmons of the maxillofacial area immunogenesis (IL-6 (14.6-34.8 ng/l), IL-8 (17.3-26.8 ng/l), IL-17 (17.0-20.9 ng/l)) is important information pointing at the necessity of the relevant care delivery aimed at the prevention of possible complications and vocational rehabilitation. 
ДИНАМИКА ПРОВОСПАЛИТЕЛЬНЫХ ЦИ-ТОКИНОВ ПРИ ФЛЕГМОНАХ ЧЕЛЮСТНО-ЛИЦЕВОЙ ОБЛАСТИ
Флегмоны челюстно-лицевой области, несмотря на со-вершенствование лечения и диагностики, занимают одно из первых мест в клинике челюстно-лицевой хирургии. Исследованы содержание провоспалительных цитоки-нов 6, 8, 17 в сыворотке крови больных с флегмонами челюстно-лицевой области в динамике лечения. Показано, что содержание цитокинов у этих пациентов был выше, чем в контрольной группе. Установлено, что сохранение высокого содержания интерлейкина-6 (IL-6, 14,6-34,8 нг/л), IL-8 (17,3-26,8 нг/л), IL-17 (17,0-20,9 нг/л) в те-чении периода лечения (9 суток) приводит к развитию осложнений, прогрессированию гнойно-воспалительного процесса. Итак, избыточная продукция цитокинов при-водит к развитию тяжелых патологических состояний в организме. В динамике лечения установлены сильные прямые корреляционные связи между IL-6 и IL-17, IL-8 и IL-17, которые могут указывать на совмещенное синерге-тическое воздействие исследуемых цитокинов. Оценка со-держания этих цитокинов в динамике заболевания может быть важной для своевременного выявления осложнений, определение стратегии лечения больных с флегмонами челюстно-лицевой области. Ключевые слова: флегмоны челюстно-лицевой области; интерлейкин-6; интерлейкин-8; интерлейкин-17.
